Roche announced that it acquired Stratos Genomics, an early-stage sequencing technology company, to advance the development of Roche’s nanopore sequencer, according to a news release.
Roche said the investment will help it reach its goal of developing an end-to-end sequencing solution, starting from a patient sample to a diagnostic result.
Once developed, the Roche nanopore sequencer will utilize an approach that combines electronic and biological components to sequence DNA for fast, flexible, and cost-effective clinical diagnostic testing, the company said.
Stratos Genomics will continue operations in Seattle. Financial details of the agreement were not disclosed.
About the Author
Sign up for our eNewsletters
Get the latest news and updates